Teva (Jerusalem, Israel), the world?s largest generics company, and Lonza (Basel, Switzerland) have formed a joint venture to develop, manufacture, and market biosimilars.
Teva (Jerusalem, Israel), the world’s largest generics company, and Lonza (Basel, Switzerland) have formed a joint venture to develop, manufacture, and market biosimilars.
Lonza, one of the largest biopharmaceutical contract manufacturing organizations, is confident that its foray into biosimilars will not interfere with its ongoing work for innovator companies. To protect its customers’ intellectual property, Lonza will not develop biosimilars for any product made by its current customers.
“The joint venture has been very carefully designed so that we cannot work on any biosimilar product for which we do not have the legal or ethical freedom to do so,” said Dominik Werner, a Lonza spokesperson. “Our work for innovator companies remains our core business.”
While developing its strategy for the biosimilars market, Lonza discussed the idea with current customers, and came to the conclusion that they would not be scared off.
“Innovator companies understand the attractiveness of the biosimilars market,” Werner said. “There has been a mindshift, and many of them are also taking steps in this direction.”
Pending regulatory approval of the partnership, activity in the joint venture will begin this quarter, and the companies expect their first product will be approved by 2014.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.